The clinical trial sponsored by Xuzhou Medical University aims to evaluate a novel CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML). Given the high unmet medical need in this patient population, successful outcomes could position this therapy as a competitive alternative to existing treatments, potentially capturing significant market share in the CAR-T space. The collaboration with Yake Biotechnology Ltd. may enhance development capabilities and commercialization prospects. However, the trial's not-yet-recruiting status indicates that market entry is still several years away, with estimated completion in 2029. Stakeholders should monitor the evolving landscape of AML therapies and the competitive positioning of this asset as it progresses through clinical development.